Grégory Driessens

Ineos (Belgium) — Belgium

Immunology and Microbiology · Life Sciences

17h-index3.3kcitations80works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(25), Immunotherapy and Immune Responses(18), Tryptophan and brain disorders(17), Cancer Immunotherapy and Biomarkers(14), T-cell and B-cell Immunology(13)

Publications79 total

a-TIGIT mAb belrestotug in combination with anti-PD1 induces an immunocompetent tumor microenvironment (TME)
2025Open Access
74 Abstract withdrawn
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
Supplementary Tables 1-2 and Figures 1-10 from Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors
2023Open Access
Data from Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors
2023Open Access
Data from Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors
2023Open Access
Supplementary Tables 1-2 and Figures 1-10 from Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors
2023Open Access
Data from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023Open Access
Data from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Supplementary Data from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023Open Access
Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Table S1, Table S3, Figures S1-S8 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Supp Figures from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023Open Access
Data from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023Open Access
Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Supp Figures from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023Open Access
Supplementary Data from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023Open Access
Table S1, Table S3, Figures S1-S8 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Supplementary Methods from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Supplementary Methods from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Data from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Reece Marillier(14), Stefano Crosignani(13), Julie Preillon(13), Romain Pirson(12), Sofie Denies(11), Virginie Rabolli(11), Noémie Wald(10), Thomas F. Gajewski(9), Marjorie Mercier(9), Erica Houthuys(9), Catherine Bruyns(9), Julia Cuende(8), Margreet Brouwer(8), Florence Nyawouame(8), Thierry Velu(8), Sandra Cauwenberghs(7), Shruthi Prasad(7), Florence Lambolez(7), João Marchante(7), Catherine Hoofd(7)